Skip to content

Drug interactions

Pasireotide + Umeclidinium-vilanterol

Severity: Moderate

Pasireotide and Umeclidinium-vilanterol: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Pasireotide can prolong the QT interval and slow heart rate. Vilanterol may add to arrhythmia risk through beta-adrenergic effects and lower potassium.

What this interaction means in plain words

Pasireotide and Umeclidinium-vilanterol can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Pasireotide belongs to Endocrine; Umeclidinium-vilanterol belongs to Respiratory.

Evidence level: Low

Why it happens

Additive effects on cardiac repolarization and beta-adrenergic cardiac stimulation.

What to do

Obtain a baseline ECG and monitor it, and correct potassium and magnesium during pasireotide therapy. Reassess the combination if the QTc becomes prolonged.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Pasireotide and Umeclidinium-vilanterol, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Pasireotide with Umeclidinium-vilanterol?

MediHelp rates the interaction as moderate. Pasireotide and Umeclidinium-vilanterol can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Pasireotide can prolong the QT interval and slow heart rate. Vilanterol may add to arrhythmia risk through beta-adrenergic effects and lower potassium.

How serious is the interaction between Pasireotide and Umeclidinium-vilanterol?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Obtain a baseline ECG and monitor it, and correct potassium and magnesium during pasireotide therapy. Reassess the combination if the QTc becomes prolonged.

What other medicines interact with Umeclidinium-vilanterol?

MediHelp also lists interactions of Umeclidinium-vilanterol with, for example, Aclidinium, Amiodarone, Amitriptyline. The full list is on the Umeclidinium-vilanterol page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in